title: Insulin inhibits nuclear phosphatase activity: requirement for the C-terminal domain of the insulin receptor.
abstract: Insulin's interaction with its receptor initiates a multitude of cellular effects on metabolism, growth, and differentiation. We recently described an insulin-mediated inhibition of nuclear protein phosphatase 2A (PP-2A), which is associated with an increase in phosphorylation of the transcription factor cAMP response element-binding protein. To clarify the role of nuclear PP-2A inhibition in the insulin signaling cascade, we examined the regulation of this phosphatase activity by insulin in Rat-1 fibroblasts overexpressing normal (HIRc) or mutant human insulin receptors (delta CT cells, deletion of a 43-amino acid C-terminal domain). The delta CT cells represent an excellent model of impaired metabolic and intact mitogenic action of insulin. Insulin inhibited nuclear PP-2A activity and enhanced cAMP response element-binding protein phosphorylation in HIRc cells, but not in delta CT cells. The delta CT cells exhibited normal ras activation and blunted mitogen-activating protein kinase phosphorylation and activation in response to insulin (16-fold in HIRc cells vs. 3-fold in delta CT cells), indicating that the mitogen-activating protein kinase pathway is important for the regulation of nuclear PP-2A activity by insulin. We conclude that insulin inhibits nuclear PP-2A activity, and that the carboxy-terminal domain of the insulin receptor is important for this effect.
authors.affiliation: Medical Research Service, Veterans Affairs Medical Center, Denver, Colorado 80220, USA.
authors.forename: J E
authors.initials: JE
authors.lastname: Reusch
authors.forename: P
authors.initials: P
authors.lastname: Hsieh
authors.forename: P
authors.initials: P
authors.lastname: Bhuripanyo
authors.forename: K
authors.initials: K
authors.lastname: Carel
authors.forename: J W
authors.initials: JW
authors.lastname: Leitner
authors.forename: J M
authors.initials: JM
authors.lastname: Olefsky
authors.forename: B
authors.initials: B
authors.lastname: Draznin
mesh_terms: D051697:Activating Transcription Factor 1; D000818:Animals; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000378:metabolism; D002460:Cell Line; D002467:Cell Nucleus / Q000187:drug effects* / Q000378:metabolism*; D017362:Cyclic AMP Response Element-Binding Protein / Q000378:metabolism; D004268:DNA-Binding Proteins; D006801:Humans; D007328:Insulin / Q000494:pharmacology*; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors*; D054648:Protein Phosphatase 2; D051381:Rats; D011972:Receptor, Insulin / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D017384:Sequence Deletion; D014157:Transcription Factors / Q000378:metabolism; D014162:Transfection
chemical_list: D051697:Activating Transcription Factor 1; D017362:Cyclic AMP Response Element-Binding Protein; D004268:DNA-Binding Proteins; D007328:Insulin; D014157:Transcription Factors; D011972:Receptor, Insulin; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D010749:Phosphoprotein Phosphatases; D054648:Protein Phosphatase 2